HAYWARD, Calif. – Eikon Therapeutics, Inc., a pioneering biotechnology company that leverages advanced engineering to enhance drug discovery and development, today announced that CEO and Board Chair, Roger M. Perlmutter, M.D., Ph.D., will provide a business update highlighting pipeline and clinical development progress in a presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 09:00 AM Pacific Standard Time.
Additional information about Eikon Therapeutics can be found on the company’s website at: www.EikonTx.com.
About Eikon Therapeutics
Eikon Therapeutics seeks to advance breakthrough therapeutics through the purposeful integration of engineering and science. Our proprietary discovery technologies leverage Nobel Prize-winning super-resolution microscopy, advanced engineering, and high-performance computing to visualize and measure the real-time movement of proteins in living cells, with the goal of bringing important new medicines to people suffering from grievous illness. Eikon operates from its facilities in California, New Jersey, and New York and can be found online via our website or LinkedIn.